Trial Profile
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2018
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary) ; Influenza virus vaccine
- Indications Asthma
- Focus Pharmacodynamics; Registrational
- Acronyms ALIZE
- Sponsors AstraZeneca
- 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 19 Jan 2017 Status changed from active, no longer recruiting to completed.
- 29 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Jan 2017.